ABBV · News · 20260910N

Revenue Performance and Mix

AbbVie Inc. · 2026-09-10 · Importance 60 · Surprise 24

Skyrizi and Rinvoq generated more than half of AbbVie’s total revenue in the first half of 2026, according to third-party reporting. The products replaced revenue lost from Humira biosimilar erosion. AbbVie anticipates combined Skyrizi and Rinvoq sales will exceed $31 billion in 2026.